Bank Of America Corp Red Hill Biopharma Ltd. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.14 - $695.9 $478 - $2.38 Million	-3,416 Reduced 72.31%	1,308 $0
Q3 2022 Nov 14, 2022	BUY	$0.5 - $523.8 $1,712 - $1.79 Million	3,424 Added 263.38%	4,724 $3,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.58 $523 - $2,143	-831 Reduced 39.0%	1,300 $1,000
Q1 2022 May 16, 2022	SELL	$1.65 - $3.12 $569 - $1,076	-345 Reduced 13.93%	2,131 $5,000
Q4 2021 Feb 08, 2022	SELL	$2.31 - $5.85 $29,025 - $73,505	-12,565 Reduced 83.54%	2,476 $5,000
Q3 2021 Nov 15, 2021	BUY	$4.55 - $10.36 $33,160 - $75,503	7,288 Added 94.0%	15,041 $69,000
Q2 2021 Sep 13, 2021	BUY	$5.98 - $7.51 $46,362 - $58,225	7,753 New	7,753 $54,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.